Keung A - Search Results

1

Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable.

Fätkenheuer G, Hoffmann C, Slim J, Rouzier R, Keung A, Li J, Treitel M, Sansone-Parsons A, Kasserra C, O'Mara E, Schürmann D. Fätkenheuer G, et al. Among authors: keung a. J Acquir Immune Defic Syndr. 2010 Jan;53(1):78-85. doi: 10.1097/QAI.0b013e3181bb28dc. J Acquir Immune Defic Syndr. 2010. PMID: 19838130 Clinical Trial.

2

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.

Schürmann D, Fätkenheuer G, Reynes J, Michelet C, Raffi F, van Lier J, Caceres M, Keung A, Sansone-Parsons A, Dunkle LM, Hoffmann C. Schürmann D, et al. Among authors: keung a. AIDS. 2007 Jun 19;21(10):1293-9. doi: 10.1097/QAD.0b013e3280f00f9f. AIDS. 2007. PMID: 17545705 Clinical Trial.

3

Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.

Kasserra C, Sansone-Parsons A, Keung A, Tetteh E, Assaf M, O'Mara E, Marbury T. Kasserra C, et al. Among authors: keung a. Clin Pharmacokinet. 2010 Jun;49(6):397-406. doi: 10.2165/11319470-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20481650 Clinical Trial.

4

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).

Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; ACTG A5211 Study Team. Crawford KW, et al. Among authors: keung a. J Acquir Immune Defic Syndr. 2010 Apr;53(5):598-605. doi: 10.1097/QAI.0b013e3181c9caac. J Acquir Immune Defic Syndr. 2010. PMID: 20071999 Free PMC article. Clinical Trial.

5

Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.

Banfield C, Herron J, Keung A, Padhi D, Affrime M. Banfield C, et al. Among authors: keung a. Clin Pharmacokinet. 2002;41 Suppl 1:37-44. doi: 10.2165/00003088-200241001-00006. Clin Pharmacokinet. 2002. PMID: 12169045 Clinical Trial.

6

Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.

Keung A, Reith K, Eller MG, McKenzie KA, Cheng L, Weir SJ. Keung A, et al. Int J Tuberc Lung Dis. 1999 May;3(5):426-36. Int J Tuberc Lung Dis. 1999. PMID: 10331733 Clinical Trial.

7

Single and multiple dose pharmacokinetics of rifapentine in man: part II.

Keung A, Eller MG, McKenzie KA, Weir SJ. Keung A, et al. Int J Tuberc Lung Dis. 1999 May;3(5):437-44. Int J Tuberc Lung Dis. 1999. PMID: 10331734 Clinical Trial.

8

Single-dose pharmacokinetics of rifapentine in women.

Keung AC, Eller MG, Weir SJ. Keung AC, et al. J Pharmacokinet Biopharm. 1998 Feb;26(1):75-85. doi: 10.1023/a:1023276808298. J Pharmacokinet Biopharm. 1998. PMID: 9773393

9

Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction.

Keung AC, Eller MG, Weir SJ. Keung AC, et al. J Clin Pharmacol. 1998 Jun;38(6):517-24. doi: 10.1002/j.1552-4604.1998.tb05789.x. J Clin Pharmacol. 1998. PMID: 9650541 Clinical Trial.

10

Disposition and metabolism of 14C-rifapentine in healthy volunteers.

Reith K, Keung A, Toren PC, Cheng L, Eller MG, Weir SJ. Reith K, et al. Among authors: keung a. Drug Metab Dispos. 1998 Aug;26(8):732-8. Drug Metab Dispos. 1998. PMID: 9698286

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters